NCT02930694View on ClinicalTrials.gov

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Healthy
Interventions
DRUG

JNJ-54175446 (capsule)

Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.

DRUG

JNJ-54175446 (suspension)

Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02930694 - A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants | Biotech Hunter | Biotech Hunter